Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01536535 · ClinicalTrials.gov registry record · Phase 4

Predicting Response to Standardized Pediatric Colitis Therapy

A Phase 4 study, sponsored by Connecticut Children's Medical Center.

Completed
Registry status
Phase 4
Development phase
431
Enrollment target

NCT01536535 is a Phase 4 study that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 431 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01536535, a Phase 4 study, has completed, sponsored by Connecticut Children's Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
431 participants
Enrollment target

Study Summary

This is a multi-center, open-label study to determine the safety and effectiveness (how well it works) of two standardized treatments called "mesalamine" (Pentasa®) and "prednisone" in children with newly diagnosed Ulcerative Colitis (UC). Standardized treatments are types of treatments agreed upon and used by many qualified doctors. The medications being used in this study are considered "standard of care". Currently the ways in which these medicines are used (doses, frequency of dosing) may vary from site to site. This study will determine response to a standardized way of giving these medicines. This study will also identify biomarkers for ulcerative colitis. Biomarkers are things that doctors can find in blood, stool, or bowel tissue that indicate how much inflammation there is in the bowel, how the inflammation is produced, and whether the inflammation is responding to treatment. Collecting response and remission (free of symptoms) information on these standardized treatments and the "biomarkers" can possibly help doctors create a model, or plan to know which children with UC may respond quickly, or which children may develop complications.

Interventions

  • DRUG Oral Corticosteroids
  • DRUG Mesalazine
  • DRUG IV Corticosteroid
  • OTHER Additional Therapies
  • PROCEDURE Colectomy

Trial Details

FieldValue
Enrollment Target 431 participants
Start Date 2012-07-10
Est. Completion 2018-04-30
Phase Phase 4

What the Registry Record Tells You About NCT01536535

The ClinicalTrials.gov registry entry for NCT01536535 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 431 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connecticut Children's Medical Center, which has 55 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Oral Corticosteroids is the first listed.

NCT01536535 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01536535 about?

NCT01536535 is a clinical study titled "Predicting Response to Standardized Pediatric Colitis Therapy". This is a multi-center, open-label study to determine the safety and effectiveness (how well it works) of two standardized treatments called "mesalamine" (Pentasa®) and "prednisone" in children with newly diagnosed Ulcerative Colitis (UC). Standardized treatments are types of treatments agreed upon ...

What is the current status of trial NCT01536535?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 431 participants. The study started on 2012-07-10. Estimated completion is 2018-04-30.

What interventions are being tested in trial NCT01536535?

The interventions under investigation include: Oral Corticosteroids (DRUG), Mesalazine (DRUG), IV Corticosteroid (DRUG), Additional Therapies (OTHER), Colectomy (PROCEDURE).

Who is sponsoring clinical trial NCT01536535?

This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.